EXPLORE THE UNIVERSITY OF OXFORD'S WORLD-CLASS RESEARCH

1 entry found
1
Journal article icon
Journal article

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

  • HPS2-THRIVE Collaborative Group, Jiang, L, Hopewell, J, et al.
  • 2013-05-01
File available icon
Peer reviewed icon
Link to publisher copy available icon
FILTER RESULTS

TO TOP